These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22560300)

  • 41. Lysophosphatidylcholine and its phosphorothioate analogues potentiate insulin secretion via GPR40 (FFAR1), GPR55 and GPR119 receptors in a different manner.
    Drzazga A; Kristinsson H; Sałaga M; Zatorski H; Koziołkiewicz M; Gendaszewska-Darmach E; Bergsten P
    Mol Cell Endocrinol; 2018 Sep; 472():117-125. PubMed ID: 29225068
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Current status of clinical development of novel anti-diabetic drugs].
    Kamiyama H; Terauchi Y
    Nihon Rinsho; 2015 Mar; 73(3):517-22. PubMed ID: 25812383
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus.
    Manaithiya A; Alam O; Sharma V; Javed Naim M; Mittal S; Khan IA
    Bioorg Chem; 2021 Aug; 113():104998. PubMed ID: 34048996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells.
    Sakamoto Y; Inoue H; Kawakami S; Miyawaki K; Miyamoto T; Mizuta K; Itakura M
    Biochem Biophys Res Commun; 2006 Dec; 351(2):474-80. PubMed ID: 17070774
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GPR119, a Major Enteroendocrine Sensor of Dietary Triglyceride Metabolites Coacting in Synergy With FFA1 (GPR40).
    Ekberg JH; Hauge M; Kristensen LV; Madsen AN; Engelstoft MS; Husted AS; Sichlau R; Egerod KL; Timshel P; Kowalski TJ; Gribble FM; Reiman F; Hansen HS; Howard AD; Holst B; Schwartz TW
    Endocrinology; 2016 Dec; 157(12):4561-4569. PubMed ID: 27779915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
    Matsumoto K; Yoshitomi T; Shimada T
    Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design of potent and selective GPR119 agonists for type II diabetes.
    Szewczyk JW; Acton J; Adams AD; Chicchi G; Freeman S; Howard AD; Huang Y; Li C; Meinke PT; Mosely R; Murphy E; Samuel R; Santini C; Yang M; Zhang Y; Zhao K; Wood HB
    Bioorg Med Chem Lett; 2011 May; 21(9):2665-9. PubMed ID: 21273063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
    Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
    Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
    Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
    J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
    Fyfe MC; McCormack JG; Overton HA; Procter MJ; Reynet C
    Expert Opin Drug Discov; 2008 Apr; 3(4):403-13. PubMed ID: 23489096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel class of antagonists for the FFAs receptor GPR40.
    Hu H; He LY; Gong Z; Li N; Lu YN; Zhai QW; Liu H; Jiang HL; Zhu WL; Wang HY
    Biochem Biophys Res Commun; 2009 Dec; 390(3):557-63. PubMed ID: 19818732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo efficacy of HD0471953: a novel GPR119 agonist for the treatment of type 2 diabetes mellitus.
    Kim SR; Kim DH; Park SH; Kim YS; Kim CH; Ha TY; Yang J; Rhee JK
    J Diabetes Res; 2013; 2013():269569. PubMed ID: 24386644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
    Hryciw DH; Patten RK; Rodgers RJ; Proietto J; Hutchinson DS; McAinch AJ
    Expert Opin Investig Drugs; 2024 Mar; 33(3):183-190. PubMed ID: 38372052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intestinal GPR119 activation by microbiota-derived metabolites impacts feeding behavior and energy metabolism.
    Igarashi M; Hayakawa T; Tanabe H; Watanabe K; Nishida A; Kimura I
    Mol Metab; 2023 Jan; 67():101649. PubMed ID: 36462626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and biological evaluation of a 6-aminofuro[3,2-c]pyridin-3(2H)-one series of GPR 119 agonists.
    Sakairi M; Kogami M; Torii M; Kuno Y; Ohsawa Y; Makino M; Kataoka D; Okamoto R; Miyazawa T; Inoue M; Takahashi N; Harada S; Watanabe N
    Arzneimittelforschung; 2012 Nov; 62(11):537-44. PubMed ID: 22972470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.